Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 1.00 |
| ▸ | PRKDC | P78527 | 13/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 10/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 10/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 10/20 | 1.00 |
| ▸ | SRC | P12931 | 5/20 | 0.63 |
| ▸ | ABL1 | P00519 | 3/20 | 0.63 |
| ▸ | MTOR | P42345 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | HCK | P08631 | 1/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655830 | 1.00 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30385963 | 0.84 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21048473 | 0.84 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30387188 | 0.82 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30387571 | 0.81 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30387431 | 0.81 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5136625 | 0.80 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30387215 | 0.80 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30386831 | 0.80 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5065412 | 0.80 | PIK3CD (1.00) | PIK3CDPRKDCPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | PIK3CD 12/4885PRKDC 189/4885PIK3CA 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.